EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparative genomic landscape of lower-grade glioma and glioblastoma

Xinxin Sun iD, Qingbin Jia, Kun Li, Conghui Tian, Lili Yi, Lili Yan, Juan Zheng, Xiaodong Jia, Mingliang Gu iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0309536 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift PLOS ONE, 2024. Verfasst von Xinxin Sun und 8 weiteren Autor:innen. Beteiligte Einrichtung: Joint Laboratory for Translational Medicine Research, Liaocheng People's Hospital, Liaocheng, Shandong, China. Hauptthemen laut MEDLINE: Glioblastoma, Isocitrate Dehydrogenase, Glioma, Mutation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biomarkers for classifying and grading gliomas have been extensively explored, whereas populations in public databases were mostly Western/European. Based on public databases cannot accurately represent Chinese population. To identify molecular characteristics associated with clinical outcomes of lower-grade glioma (LGG) and glioblastoma (GBM) in the Chinese population, we performed whole-exome sequencing (WES) in 16 LGG and 35 GBM tumor tissues. TP53 (36/51), TERT (31/51), ATRX (16/51), EFGLAM (14/51), and IDH1 (13/51) were the most common genes harboring mutations. IDH1 mutation (c.G395A; p.R132H) was significantly enriched in LGG, whereas PCDHGA10 mutation (c.A265G; p.I89V) in GBM. IDH1 -wildtype and PCDHGA10 mutation were significantly related to poor prognosis. IDH1 is an important biomarker in gliomas, whereas PCDHGA10 mutation has not been reported to correlate with gliomas. Different copy number variations (CNVs) and oncogenic signaling pathways were identified between LGG and GBM. Differential genomic landscapes between LGG and GBM were revealed in the Chinese population, and PCDHGA10 , for the first time, was identified as the prognostic factor of gliomas. Our results might provide a basis for molecular classification and identification of diagnostic biomarkers and even potential therapeutic targets for gliomas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaIsocitrate DehydrogenaseGliomaMutationDNA Copy Number VariationsBrain NeoplasmsHumansMaleFemaleMiddle AgedAdultExome SequencingTelomeraseBiomarkers, TumorNeoplasm GradingCadherinsX-linked Nuclear ProteinTumor Suppressor Protein p53AgedPrognosisGenomicsProtocadherinsYoung Adult

Substanzen

Isocitrate DehydrogenaseIDH1 protein, humanTERT protein, humanTelomeraseBiomarkers, TumorCadherinsX-linked Nuclear ProteinTumor Suppressor Protein p53ATRX protein, humanProtocadherins

Autor:innen und Institutionen

  • Joint Laboratory for Translational Medicine Research, Liaocheng People's Hospital, Liaocheng, Shandong, China.
  • Department of Neurosurgery, Liaocheng People's Hospital, Liaocheng, Shandong, China.

ORCID-Profile: Xinxin Sun, Mingliang Gu

Zitieren

APA

Sun, X., Jia, Q., Li, K., Tian, C., Yi, L., Yan, L., Zheng, J., Jia, X., & Gu, M. (2024). Comparative genomic landscape of lower-grade glioma and glioblastoma. PLOS ONE. https://doi.org/10.1371/journal.pone.0309536

Vancouver

Sun X, Jia Q, Li K, Tian C, Yi L, Yan L, et al. Comparative genomic landscape of lower-grade glioma and glioblastoma. PLOS ONE. 2024. doi:10.1371/journal.pone.0309536

BibTeX
@article{Sun2024,
  author = {Sun, Xinxin and Jia, Qingbin and Li, Kun and Tian, Conghui and Yi, Lili and Yan, Lili and Zheng, Juan and Jia, Xiaodong and Gu, Mingliang},
  title = {Comparative genomic landscape of lower-grade glioma and glioblastoma},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0309536}
}
Kostenlos starten →